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Candida albicans colonization is required for invasive disease [1] [2] [3] . Unlike humans, adult mice with mature intact gut microbiota are resistant to C. albicans gastrointestinal (GI) colonization 2, 4 , but the factors that promote C. albicans colonization resistance are unknown. Here we demonstrate that commensal anaerobic bacteria-specifically clostridial Firmicutes (clusters IV and XIVa) and Bacteroidetes-are critical for maintaining C. albicans colonization resistance in mice. Using Bacteroides thetaiotamicron as a model organism, we find that hypoxia-inducible factor-1a (HIF-1a), a transcription factor important for activating innate immune effectors, and the antimicrobial peptide LL-37 (CRAMP in mice) are key determinants of C. albicans colonization resistance. Although antibiotic treatment enables C. albicans colonization, pharmacologic activation of colonic Hif1a induces CRAMP expression and results in a significant reduction of C. albicans GI colonization and a 50% decrease in mortality from invasive disease. In the setting of antibiotics, Hif1a and Camp (which encodes CRAMP) are required for B. thetaiotamicron-induced protection against C. albicans colonization of the gut. Thus, modulating C. albicans GI colonization by activation of gut mucosal immune effectors may represent a novel therapeutic approach for preventing invasive fungal disease in humans.
Commensal fungi, mostly Candida spp., have been detected in the GI tracts of various mammals 5 . Although reportedly 40-60% of humans are colonized with C. albicans (CA) in the GI tract, adult mice are resistant to GI colonization by CA 2, 4 . Because colonization is a prerequisite for CA invasive disease [1] [2] [3] and CA colonization resistance is abrogated by antibiotic treatment 4 , understanding of the factors that modulate CA colonization could lead to novel methods for preventing CA dissemination.
Commensal anaerobic bacteria in the GI tract provide an important defense mechanism against infections by inhibiting the growth of potentially pathogenic bacteria 6, 7 . One mechanism for GI colonization resistance involves stimulation of the mucosal immune system by members of 'beneficial' microbiota 8 . Yet there have been no studies to date examining a commensal bacteria-or host-mediated immune response that modulates fungal colonization. Thus, we asked whether identifying a single bacterial species that promotes CA colonization resistance could help unveil host immune effectors critical for maintaining CA colonization resistance in the mouse GI tract.
To determine the effect of specific antibiotics on CA colonization resistance, we treated mice with various antibiotics for 5 d, orally challenged them with CA, and then assessed their susceptibility to CA colonization. CA was unable to establish sustained GI colonization in adult control (no antibiotic treatment) mice (Fig. 1a) , regardless of the mouse strain tested (Supplementary Table 1 ). In the treatment groups, CA colonization levels were directly proportional to how effective the specific antibiotic was in depleting anaerobic bacteria: penicillin G (PCN) > clindamycin > metronidazole > streptomycin (STR) (Fig. 1a and Supplementary Table 2) 9 . In fact, CA GI colonization levels in PCN-treated mice were comparable to colonization levels in non-antibiotic-treated, germ-free mice (Fig. 1b) . Even CA strains that had been serially passaged through the GI tract of an antibiotic-treated mouse could not persistently colonize a mouse GI tract with an intact gut microbiome ( Supplementary Fig. 1a,b) .
The gut microbiota in infant humans and mice have substantially fewer commensal anaerobes than those in adults 10, 11 . Hence, CA established persistent GI colonization in postnatal day (P)14 and P28 mice but not in adolescent (P42) animals ( Fig. 1c and Supplementary  Table 2 ). Other CA strains, including two clinical isolates ( Fig. 1d and Supplementary Table 3) , and other Candida spp. that infect humans (Fig. 1e) were also unable to colonize mice with intact gut microbiota (Supplementary Table 2 ). Together, these findings indicate that a mature adult bacterial microbiota, particularly comprising commensal anaerobes, is essential for maintaining CA colonization resistance.
To identify specific members of the gut microbiota essential for maintaining CA colonization resistance, we profiled the gut microbiomes (using 16S rRNA sequencing and bacterial group quantitative PCR (qPCR)) of CA colonization-resistant (no antibiotic treatment or STR-treated) or CA colonization-susceptible (treated with PCN or PCN and STR (PS)) mice (Fig. 2a) . The bacterial phyla Firmicutes and Bacteroidetes account for >95% of the bacteria in the distal guts of healthy adult mice and humans 11 . The abundance of FirmicutesBacteroidetes markedly decreased in CA-colonized (PCN-or PS-treated) mice compared to colonization-resistant (sterile water-or STRtreated) mice (Fig. 2b) . PCN-treated mice exhibited the most significant decrease (3-4 log fold) in total gut bacteria (eubacteria, EUBAC) by qPCR compared to the more modest 0.5 log fold reduction seen in the STR-treated group (Fig. 2c) . Streptomycin is an antibiotic that is effective against Gram-negative bacteria and completely ineffective against obligate anaerobic bacteria 12 . PCN-treated mice had marked decreases in all bacterial groups, with the exception of Proteobacteria and Enterobacteriaceae (ENTERO). Penicillin G has activity against Gram-positive bacteria and anaerobes, but it is ineffective against Gram-negative bacteria 13 (Fig. 2c) . Notably, endogenous gut fungi (which include some Candida spp., but not CA) increased significantly (P = 0.029, Mann-Whitney) in mice treated with antibiotics (e.g., PCN) active against Bacteroidetes (mouse intestinal Bacteroides, MIB) and clostridial Firmicutes (clostridial cluster XIVa, EREC; and clostridial cluster IV, CLEPT) ( Supplementary Fig. 2) . Thus, only antibiotic treatment that sufficiently depleted anaerobic bacteria (e.g., PCN) was sufficient to overcome CA colonization resistance in the mouse GI tract.
We postulated that cessation of antibiotics in CA-colonized mice would allow suppressed bacterial groups to regrow and restore CA colonization resistance. Indeed, CA colonization levels steadily decreased and were undetectable 35 d after antibiotic cessation (Fig. 2d) . Overall bacterial levels (EUBAC) returned to pre-antibiotic-treated levels 14 d after stopping antibiotics (Fig. 2e) . Notably, Bacteroidetes and clostridial Firmicutes increased significantly (although they still remained lower than baseline), whereas Lactobacillus (LACT), segmented filamentous bacteria (SFB) and ENTERO remained suppressed for the duration of the experiment (Fig. 2e) . In total, these findings suggested that Bacteroidetes and clostridial Firmicutes may be the bacterial groups most effective in promoting CA colonization resistance.
To test this hypothesis, we performed oral bacterial add-back experiments in antibiotic-treated CA-colonized mice. Notably, among Bacteroidetes, the addition of Bacteroides fragilis did not significantly change CA colonization levels compared to a no-bacteria control group, whereas the presence of Bacteroides thetaiotamicron (B. theta) resulted in undetectable CA levels in all mice 14 d after bacterial inoculation ( Fig. 2f and Supplementary Table 3) . Similarly, among Firmicutes, Blautia producta promoted complete elimination of CA, whereas the Lactobacillus spp. (L. acidophilus and L. reuteri) did not consistently eliminate CA colonization (Fig. 2f) . Both members of the phylum Proteobacteria (Escherichia coli and Pseudomonas aeruginosa), however, had no significant effect on CA (Fig. 2f) . Collectively, these experiments showed that individual Firmicutes and Bacteroidetes species are sufficient to promote CA colonization resistance in the gut.
Because B. theta and B. producta had the most significant (P = 0.0002 for both B. theta and B. producta, Mann-Whitney) effect in our model, we replicated these experiments in germ-free mice that can be colonized with CA without antibiotic pretreatment. Although B. producta and B. theta GI levels remained consistent throughout the duration of the experiment, CA levels steadily decreased and were undetectable by day 20 in the B. producta group (Fig. 2g) , and they significantly decreased (nearly 5 log fold) but remained detectable in the B. theta group (Fig. 2h) .
Overall, we found that only antibiotics that depleted anaerobic bacteria were sufficient to overcome CA colonization resistance. Among the bacteria we tested, clostridial Firmicutes and Bacteroidetes most effectively fostered colonization resistance, although individual bacterial species varied greatly in this ability. Ultimately, we identified two genetically distinct bacterial species, B. theta and B. producta, that individually promoted CA colonization resistance.
B. theta and B. producta induces host immune effectors critical for maintaining colonization resistance, and we focused on the transcription factor HIF-1α and the antimicrobial peptide LL-37 (CRAMP). HIF-1α is an essential regulator of mammalian innate defense 14 , and it increases expression of antimicrobial cathelicidin peptides 15 in myeloid cells. Cathelicidin-related antimicrobial peptides are a family of polypeptides that serve a critical role in mammalian innate immune defense against bacterial infection 14, 15 . The human cathelicidin LL-37 has been shown to have anti-Candida activity 16 and to inhibit CA adhesion to epithelial surfaces 17 . Notably, mRNA expression of Hif1a and Camp (cathelicidin-related antimicrobial peptide, the LL-37 ortholog) significantly increased in colonization-resistant mice compared to CA-colonized mice (Fig. 3a,b ). Both HIF1A (or Hif1a) and CAMP (or Camp) expression markedly increased in human colonocytes (HT-29 cells) exposed to CA (or in the colon of CA-colonized, antibiotic-treated mice) (Fig. 3c,d) . The colon had the highest concentration of fungi ( Supplementary Fig. 3) , and thus all of our experiments use colons. Of note, other Candida spp. also induced mouse colonic expression of Hif1a and Camp (Supplementary Fig. 4) . Interestingly, B. theta and B. producta induced a significantly greater degree of mouse colonic Hif1a (mRNA) and Camp and CRAMP (mRNA and protein) expression ( Fig. 3e-h ) compared to other commensal bacteria that we tested in the bacterial add-back experiments. In germ-free mice, co-colonization with B. theta and CA induced greater colonic Hif1a and Camp expression (Fig. 3i,j 18, 19 . In fact, bacterially produced SCFAs at physiologically relevant doses 20 inhibited CA growth in vitro and diminished CA colonization in mice, although not to the degree seen with B. theta, suggesting that the host response is important in order to completely suppress CA colonization (Supplementary Fig. 5 ).
To further test whether HIF-1α or LL-37 is required to prevent CA colonization, we first used a well-established HIF-1α agonist, l-mimosine 21 (mimosine), in an in vitro fungicidal assay using cultured human colonocytes. mRNA and protein expression of both HIF1A and CAMP increased in colonocytes exposed to mimosine ( Supplementary Fig. 6a-c) . Mimosine stabilizes HIF-1α through inhibition of prolyl hydroxylases and inhibits HIF-1α degradation 14 . This probably explains the modest increase in HIF1A gene expression compared to the more pronounced increase in LL-37 protein expression. We observed that the candidacidal activity of LL-37, confirmed using a spot assay 22 , is enhanced at lower pH values, as has been previously reported with LL-37 and other antifungal agents 16 (Supplementary Fig. 6d ). Of note, the pH in the more-distal segments of the intestine is acidic, ranging npg from pH 6.4-7.5 in the small intestine to pH 6.4-7.0 in the colon 23 . Furthermore, the distal intestine has the lowest oxygen tension in the GI tract 24 , and, in principle, could directly impact HIF-1α activation and LL-37 expression. HT-29 colonocytes pretreated with mimosine significantly reduced fungal levels in a dose-dependent manner (Supplementary Fig. 6e ), but this effect was diminished when we knocked down HIF1A mRNA expression (Supplementary Fig. 6f-h) . Also, mimosine did not inhibit the growth of CA in the absence of cocultured colonocytes (Supplementary Fig. 6i) . Thus, pharmacological activation of HIF-1α in colonocytes is required for mimosine-dependent killing of CA.
We next tested the importance of HIF-1α and CRAMP in vivo using genetically engineered mice. We demonstrated that CA GI colonization levels significantly decreased in mice treated with mimosine, but that this effect was nullified in mimosine-treated mice that had Hif1a specifically deleted from their intestinal epithelium (Hif1a fl/fl Vil-Cre + mice, Fig. 4) . In prior observations, mortality from invasive disease significantly decreased in mice with CA GI colonization levels < 10 7 CFU/g feces (data not shown). Thus, we administered cyclophosphamide to induce disseminated disease 4 . Strikingly, mice treated with mimosine had a 50% reduction in overall mortality (P = 0.038 by Fisher's exact test) and significantly increased length of survival (P < 0.001 by log-rank test) compared to their untreated counterparts (Fig. 4c) . Further, mimosine treatment had no measurable effect on survival in Hif1a fl/fl Vil-Cre + mice (Fig. 4c) . We confirmed a reduction in colonization levels and increased length of survival (P = 0.0082 by log-rank test, Supplementary Fig. 7 ) when using a second CA strain, CAF2-1.
We next examined whether CRAMP was necessary for the mimosine-induced antifungal effects that we observed. First, we verified that colonic Hif1a and Camp mRNA expression significantly increased in mimosine-treated mice (Fig. 4e) . Second, Camp-knockout mice treated with mimosine showed neither a significant decrease in C. albicans GI colonization levels (Fig. 4b) nor a decrease in mortality after administration of cyclophosphamide (Fig. 4d) compared to untreated controls. As expected, colonic Hif1a mRNA expression significantly increased, and Camp expression was negligible in mimosine-treated Camp-knockout mice (Fig. 4e,f) . 
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In mice pretreated with antibiotics (PS) and then co-colonized with CA and B. theta, HIF-1α and CRAMP were required for B. thetainduced protection against CA colonization of the gut (Fig. 4g) . In the absence of antibiotics, HIF-1α or CRAMP was not necessary to maintain CA colonization resistance in mice, which we attribute to the presence of other redundant immune pathways that may aid in maintaining CA colonization resistance when a mature and intact gut microbiota is present (Supplementary Fig. 8) .
Humans are considered the main reservoir of CA 25 . Reportedly 40-80% of humans living in westernized societies are colonized with CA 26 , but more recent studies of humans living in remote and traditional societies exhibit a CA GI carriage rate of less than 10% 27, 28 . An ongoing study of human subjects suggests that the CA carriage rate in humans may be lower than previously reported (data not shown). Thus, CA might not be a "normal" commensal of the human gut, but a more recently acquired commensal resulting from medical advances (for example, antibiotic use) and adoption of Western diets.
Commensal anaerobes, which account for >99% of all gut bacteria [29] [30] [31] , are needed to maintain CA colonization resistance in mice. Notably, we show that two anaerobic species belonging to the same genus, Bacteroides fragilis and Bacteroides thetaiotamicron, had markedly different effects on CA colonization: B. theta reduced CA colonization but B. fragilis did not. This discrepancy is probably explained by differing commensal bacteria-host immune response effects (Fig. 3e-h) . Furthermore, B. theta has been shown to stimulate production of other antimicrobial peptides (RegIIIγ (ref. 32), Ang4 (ref. 33)) that may result in fungal killing. In contrast, B. fragilis has been shown to control activation of T cell-dependent immune responses 34 , which we have previously shown to have no effect on CA GI colonization in mice 4 . Similarly, L. acidophilus reduces Candida colonization in the stomachs of mice 35 , but we did not see this effect of L. acidophilus in the distal gut. In contrast, L. reuteri significantly (P = 0.0025, Mann-Whitney) decreased CA colonization and merits further study. Identifying distinct bacterial species may allow us to uncover other host immune effectors that promote CA colonization resistance.
In a stressed system (after exposure to antibiotics and the onset of the resultant gut dysbiosis), the magnitude of the microbiota stimulus that activates the gut's redundant systems for maintaining CA colonization resistance is markedly diminished, and we find that the elimination of select immune effectors (HIF-1α, CRAMP) is enough to nullify the CA-protective effect mediated by single bacterial species such as B. theta. These findings underline the importance of an intact gut microbiota in maintaining effective gut mucosal defenses against microbial pathogens, and they may have major clinical ramifications for patients (e.g., cancer and transplant patients) who receive broad-spectrum antibiotics and are at high risk for developing invasive fungal infections.
Probiotic therapy would seem to be an obvious approach for modulating CA colonization, and it has had some efficacy in both mice 36 and humans 37, 38 . In cancer patients, the introduction of probiotics raises the concern that the probiotic itself may cause infection. In fact, when using B. theta or B. producta as probiotic therapy in antibiotic-treated mice, we were able to prevent CA dissemination only to find occasional evidence of B. theta or B. producta dissemination (data not shown).
Pharmacologic modulation of HIF-1α levels has been explored extensively in the context of cancer therapy and angiogenesis 39, 40 . HIF-1α agonists boost the bactericidal capacity of phagocytes, and we show that they may augment the fungicidal capacity of GI epithelial cells. As noted above, another potential approach could use commensal anaerobe metabolites, such as SCFAs. Finally, because SCFAs are naturally occurring metabolites of the gut, adverse effects typically associated with pharmacologic agents may not be a concern.
In conclusion, the emergence of invasive fungal disease in humans correlates with advances in medical therapy, particularly antibiotic use and invasive surgical procedures. When augmenting innate cellular function or mucosal integrity is difficult, if not impossible (e.g., in immunocompromised patients), boosting GI mucosal immune effectors to reduce fungal burden may be the key to tipping the balance back toward homeostasis and preventing invasive fungal disease.
MeTHods
Methods and any associated references are available in the online version of the paper. Mouse studies. Mouse strains used are listed in Supplementary Table 1. All animal experiments were done in accordance with US National Institutes of Health (NIH) guidelines, the Animal Welfare Act and US federal law. The University of Texas Southwestern Medical Center's Institutional Animal Care and Use Committee approved the experimental protocol "2009-0243" that was used for this study. All animals were housed in a centralized and Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) -accredited research animal facility that is fully staffed with trained husbandry, technical and veterinary personnel. Unless otherwise noted, mice used for experiments were C3H/HeN (Harlan), sex-matched and 6-8 weeks of age. Mice within an experiment were littermates that remained cohoused in the same cage to ensure a shared microbiota. Germ-free C57BL/6 mice were maintained in isolators as described 32 .
For germ-free and neonatal/infant mouse experiments, a sample size of four per group was chosen as the best compromise between providing an adequate sample size for assessing differences in colonization balanced with the limited availability of germ-free and neonatal mice. With the antibiotic-treated mice, we used a sample size of 5-8. Inclusion/exclusion criteria were not established. No animals were excluded from analysis. Randomization was not used. For the murine studies, age and sex-matched mice were arbitrarily assigned to a treatment group (i.e., antibiotics, bacteria or mimosine). No blinding was done for mouse studies.
Conditional knockout of Hif1a in the murine intestine. Hif1a fl/fl (B6.129-Hif1a tm3Rsjo /J, C57/BL background, Jackson Laboratories, floxed at exon 2) were bred with a transgenic strain expressing Cre recombinase under the control of the murine villin promoter (B6.SJL-Tg(Vil-cre)997Gum/J, C57/BL background, Jackson Laboratories). Hif1a deletion in intestinal tissues (versus non-intestinal tissues) was confirmed by PCR on mouse genomic DNA ( Supplementary  Fig. 9 ). Hif1a mRNA levels were markedly decreased in the ileums and colons, but not in the spleens, of Hif1a fl/fl Vil-Cre + mice compared with their wild-type littermates (Supplementary Fig. 9) .
Antibiotic experiments. Mice were fed sterile or antibiotic-supplemented water and colonized with C. albicans as previously described 4 . As for oral antibiotic treatment, mice were fed sterile water with 1) 2 mg/ml streptomycin (STR), 2) 1500 U/ml penicillin G (PCN), 3) PCN/STR, 4) 0.5 mg/ml clindamycin (C) or 5) 1 mg/ml metronidazole (M) for 5 d before C. albicans administration (2 × 10 8 CFU via oral gavage) and throughout the duration of the experiment. C. albicans GI colonization levels were initially checked 7 d after oral gavage (and at other indicated times) and were enumerated by culturing fecal contents on YVG agar (yeast-peptone-dextrose agar with 0.010 mg/ml vancomycin and 0.100 mg/ml gentamicin to suppress bacterial growth) 4 . For experiments using bacteria, obligate anaerobic strains (B. fragilis, B. theta, B. producta) were cultured in GMM 41 , TYG 42 or BHI/blood media under anaerobic conditions (Coy anaerobic chamber) at 37 °C; E. coli was grown in LB and MacConkey media under aerobic conditions at 37 °C; P. aeruginosa was grown in LB and Cetrimide media under aerobic conditions at 37 °C; and Lactobacillus spp. were grown in Lactobacilli MRS medium (Difco) under aerobic or anaerobic conditions at 37 °C. Bacterial colonization levels were enumerated by growth on the appropriate selective media and identity confirmed by Gram staining, enzymatic analysis (Rapid One for Enterobacteriaceae and RapID ANA II for anaerobes, Remel) and/or 16S RNA sequencing. For dissemination experiments, cyclophosphamide (Cy) was administered as previously described 4 . Mice were monitored for mortality for 7 d. Moribund mice were euthanized. Livers were resected, homogenized and plated on YVG, MacConkey, TSA, and BHI/blood agars. The presence of a homogeneous population of creamy-white colonies on YVG and a complete absence of bacterial growth on the MacConkey (aerobic), TSA (aerobic), and BHI/Blood (anaerobic) plates were used for confirmation of C. albicans dissemination.
Antibiotic-cessation experiments. C3H/HeN mice (female, 6-8 weeks, Harlan, n = 5) were treated with PS water (starting on day −14). C. albicans (2 × 10 8 CFU) was given by oral gavage on day −7. PS water was replaced with sterile water on day 0. C. albicans GI colonization levels were quantified every 7 d thereafter.
Bacterial add-back in antibiotic-treated mice. PS-treated adult mice (C3H/ HeN, female, 6-8 weeks, n = 8 per group) were colonized with C. albicans. Mice were then gavaged with a single bacterial strain (2 × 10 8 CFU). A no-bacteria control was included. All mice were then transitioned to sterile water. Bacterial and C. albicans GI colonization levels were measured after 14 d of co-colonization.
Bacterial add-back in germ-free mice. Germ-free mice (no antibiotic treatment) were first colonized with C. albicans by oral gavage (2 ×10 8 CFU) . B. theta or B. producta was then administered by oral gavage (2 × 10 8 CFU). Bacterial and Candida colonization levels were checked every 2-3 d, up to 20 d after bacterial oral gavage.
SCFA experiments. PS-treated adult mice (C3H/HeN, female, 6-8 weeks, n = 4 per group) were colonized with C. albicans by oral gavage. Mice were then treated with PS water ± 50 mM SCFAs (butyric, acetic or propionic acid). The no-treatment control group received pH-adjusted (with HCl) PS water. Colonization levels were checked after 14 d of SCFA water treatment. Fig. 9c ). Mice were treated with PS and then colonized with C. albicans strains SC5314 or CAF2-1. Mice were treated with PS water or PS water and 500 µM l-mimosine ad libitum. PS and PS-mimosine water was changed every 2-3 days for the duration of the experiment. C. albicans GI colonization levels were checked daily for the first 5 d of mimosine treatment. Cyclophosphamide was administered to all groups on days 1, 3 and 5 of mimosine treatment to induce disseminated disease.
Creation of mouse-adapted C. albicans strains. C. albicans strains SC5314 and CAF2-1 were orally gavaged to adult mice (C3H/HeN, female, 6-8 weeks, Harlan) pretreated with penicillin-streptomycin, recovered from fecal cultures, and archived (18% glycerol frozen stock). Archived C. albicans strains were grown and administered to a new set of antibiotic-treated mice, recovered and archived again. This process was carried out for a third time. Final archived cultures were used for mouse experiments.
Isolation of bacterial and fungal genomic DNA. Fecal specimens or intestinal tract segments were collected, flash frozen with liquid nitrogen, weighed and immediately resuspended in extraction buffer (200 mM NaCl, 200 mM Tris, 20 mM EDTA, 6% SDS) and 0.5 ml of phenol-chloroform-isoamyl alcohol, pH 7.9 (Ambion) 41 . Cells were lysed by bead-beating (0.1 mm zirconia/silica beads for bacterial gDNA (BioSpec), 0.6 mm acid-washed glass beads for fungal gDNA (Sigma)) and subjected to additional phenol-chloroform extractions. Crude DNA extracts were treated with RNaseA (Qiagen) and column-purified (PCR Purification Kit, Qiagen). DNA concentrations were quantified by a fluorescence-based assay (Quant-iT PicoGreen dsDNA, Life Technologies).
Isolation of ileal and colonic intestinal epithelial cells (IECs).
To confirm deletion of Hif1a (Exon 2) in intestinal epithelial cells of Hif1a fl/fl Vil-Cre + mice, colons and ileums were isolated, opened longitudinally and rinsed with PBS. The epithelial integrity was disrupted by treatment with 1 mM dithiothreitol (DTT) for 30 min at 37 °C on a shaker, followed by vortexing for 1 min. The liberated IECs were collected, resuspended in 5 ml of 20% Percoll and overlaid on 2.5 ml of 40% Percoll in a 15-ml Falcon tube. Percoll gradient separation was performed by centrifugation at 780g for 20 min at 25 °C. The interface cells were collected and used as IECs 18 . gDNA was immediately isolated from IECs with the protocol detailed above.
Quantitative PCR for microbiota analysis. Bacterial and fungal loads were quantified by qPCR analysis (SsoAdvanced SYBR Green Supermix, Bio-Rad) of microbial gDNA using universal 16S rRNA gene or fungal internal transcribed spacer (ITS1-2) primers 43 (Supplementary Table 4) . The abundance npg of specific bacterial groups was determined by qPCR using group-specific 16S rRNA gene primers 44 . The abundance of specific Candida spp. was determined by qPCR using species-specific ITS1-2 gene primers and species-specific probes (Supplementary Table 4) . To confirm specificity, Candida spp.-specific qPCR was performed using gDNA from all the Candida species used in this study, and no false positives were noted (Supplementary Fig. 10 ). Bacterial and fungal abundance was determined using standard curves constructed with reference to cloned DNA corresponding to a short segment of the 16s rRNA or ITS1-2 genes, respectively, that was amplified using conserved specific primers (Supplementary Table 4 ). Note that qPCR measures gene copies per gram of tissue, not actual bacterial or fungal numbers or colony-forming units.
